Elicio Therapeutics, Inc.2024财年第三财季实现净利润-18.84百万美元，同比减少76.74%

市场透视11-23

11月23日，Elicio Therapeutics, Inc.（ELTX.US）公布财报，公告显示公司2024财年第三财季净利润为-18.84百万美元，同比减少76.74%；其中营业收入为0.00美元，每股基本收益为-1.39美元。从资产负债表来看，Elicio Therapeutics, Inc.（ELTX.US）总负债57.37百万美元，其中短期债务877000.00美元，资产负债比为...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2485981152?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-11-23 00:01","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2485981152","market":"us","top_or_hot":-1,"title":"Elicio Therapeutics, Inc.2024财年第三财季实现净利润-18.84百万美元，同比减少76.74%","media":"市场透视","content":"<div>\n<p>11月23日，Elicio Therapeutics, Inc.（ELTX.US）公布财报，公告显示公司2024财年第三财季净利润为-18.84百万美元，同比减少76.74%；其中营业收入为0.00美元，每股基本收益为-1.39美元。从资产负债表来看，Elicio Therapeutics, Inc.（ELTX.US）总负债57.37百万美元，其中短期债务877000.00美元，资产负债比为...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241123000141abd7b874&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Elicio Therapeutics, Inc.2024财年第三财季实现净利润-18.84百万美元，同比减少76.74%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nElicio Therapeutics, Inc.2024财年第三财季实现净利润-18.84百万美元，同比减少76.74%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-23 00:01 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241123000141abd7b874&s=b><strong>市场透视</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>11月23日，Elicio Therapeutics, Inc.（ELTX.US）公布财报，公告显示公司2024财年第三财季净利润为-18.84百万美元，同比减少76.74%；其中营业收入为0.00美元，每股基本收益为-1.39美元。从资产负债表来看，Elicio Therapeutics, Inc.（ELTX.US）总负债57.37百万美元，其中短期债务877000.00美元，资产负债比为...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241123000141abd7b874&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ELTX","symbol_name":"Elicio Therapeutics","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241123000141abd7b874&s=b","article_id":"2485981152","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241123000141abd7b874&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2485981152","pubTimestamp":1732291277,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"11月23日，Elicio Therapeutics, Inc.公布财报，公告显示公司2024财年第三财季净利润为-18.84百万美元，同比减少76.74%；其中营业收入为0.00美元，每股基本收益为-1.39美元。机构评级：截至2024年11月23日，当前有2家机构对Elicio Therapeutics, Inc.目标价做出预测，其中目标均价为9.50美元，其中最低目标价为9.00美元，最高目标价为10.00美元。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":["earning"],"viewcount":null,"language":"zh","relate_stocks":{"ELTX":"Elicio Therapeutics","LENZ":"Therapeutics"},"translate_title":"Elicio Therapeutics, Inc. achieved net profits of-18.84 million in the third fiscal quarter of fiscal 2024, a year-on-year decrease of 76.74%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ELTX":1,"LENZ":1},"content_text":"11月23日，Elicio Therapeutics, Inc.（ELTX.US）公布财报，公告显示公司2024财年第三财季净利润为-18.84百万美元，同比减少76.74%；其中营业收入为0.00美元，每股基本收益为-1.39美元。从资产负债表来看，Elicio Therapeutics, Inc.（ELTX.US）总负债57.37百万美元，其中短期债务877000.00美元，资产负债比为0.67，流动比率为3.40。机构评级：截至2024年11月23日，当前有2家机构对Elicio Therapeutics, Inc.目标价做出预测，其中目标均价为9.50美元，其中最低目标价为9.00美元，最高目标价为10.00美元。公司简介：Elicio Therapeutics Inc 是一家临床阶段的生物技术公司，致力于为治疗选择有限且结果不佳的患者开发癌症免疫疗法。 其专有的 Amphiphile（AMP）平台将研究中的免疫治疗药物直接输送到免疫系统的大脑中心和淋巴结。 其重点是针对经过生物学验证但难以药物治疗的靶点开发癌症免疫疗法，这些靶点可通过淋巴结运输激活。 Elicio 正在为一系列侵袭性癌症设计靶向淋巴结的 AMPlifiers、免疫调节剂、佐剂和疫苗。 该公司已经开发了其癌症疫苗候选产品，以使用已知的新抗原来针对经过生物学验证的肿瘤突变驱动因素。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2485981152"}